several large independent research outfits employing thousands of scientists, is seeing venture capital flow in after Merkel's federal investments. Rainer Strohmenger, at Munich-based VC outfit Wellington Partners recently commented that big pharma's top execs are coming to Germany to lay out pipeline needs. Whe